Short Interest in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Declines By 49.7%

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) was the target of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 14,700 shares, a decrease of 49.7% from the February 13th total of 29,200 shares. Based on an average daily trading volume, of 17,900 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.2% of the shares of the company are sold short.

PharmaCyte Biotech Price Performance

Shares of PMCB stock traded down $0.09 during trading hours on Friday, reaching $1.58. 25,255 shares of the company traded hands, compared to its average volume of 24,421. The firm has a 50-day moving average price of $1.65 and a 200 day moving average price of $1.69. The company has a market cap of $10.85 million, a P/E ratio of 2.98 and a beta of -0.25. PharmaCyte Biotech has a 12-month low of $1.39 and a 12-month high of $2.58.

PharmaCyte Biotech (NASDAQ:PMCB) last posted its quarterly earnings results on Friday, December 13th. The company reported ($0.29) earnings per share for the quarter.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.